StockNews.AI

Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

StockNews.AI • 3 hours

MDTSYKZBH
High Materiality9/10

Information

ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading throm...

Original source

AI Summary

PEN reported fourth quarter 2025 revenue of $383-$384.8 million, a 21.4-22% increase. Full year 2025 revenue reached $1.401-$1.403 billion, growing 17.3-17.5% YoY. Excluding China, Q4 2025 growth was around 23.2-23.8%, and 24.7-24.9% for the year. Gross margin for Q4 2025 was 67.9-68.1%, consistent with strong operational performance. PEN provides innovative thrombectomy technologies, earning a reputation for patient care improvements.

Sentiment Rationale

Strong revenue growth metrics align with positive market sentiment and performance. Historical examples, such as consistent growth from medical technology firms, suggest potential price appreciation.

Trading Thesis

Earnings announcements typically impact stock prices quickly, often within weeks. Past trends show immediate market responses to strong financial results.

Market-Moving

  • PEN reported fourth quarter 2025 revenue of $383-$384.8 million, a 21.4-22% increase.
  • Full year 2025 revenue reached $1.401-$1.403 billion, growing 17.3-17.5% YoY.
  • Excluding China, Q4 2025 growth was around 23.2-23.8%, and 24.7-24.9% for the year.

Key Facts

  • PEN reported fourth quarter 2025 revenue of $383-$384.8 million, a 21.4-22% increase.
  • Full year 2025 revenue reached $1.401-$1.403 billion, growing 17.3-17.5% YoY.
  • Excluding China, Q4 2025 growth was around 23.2-23.8%, and 24.7-24.9% for the year.
  • Gross margin for Q4 2025 was 67.9-68.1%, consistent with strong operational performance.
  • PEN provides innovative thrombectomy technologies, earning a reputation for patient care improvements.

Companies Mentioned

  • MDT (MDT)
  • SYK (SYK)
  • ZBH (ZBH)

Earnings

The financial results are significant indicators of company health and market perception.

Penumbra, Inc. Reports Preliminary Financial Results for Q4 and Full Year 2025

Penumbra, Inc. (NYSE: PEN), a leader in thrombectomy technologies, has disclosed its unaudited financial results for the fourth quarter and full year of 2025. The company reported significant revenue growth, underlining its strong performance in the medical technology space.

Financial Highlights for Q4 2025

In the fourth quarter of 2025, Penumbra's revenue ranged between $383.0 million and $384.8 million, marking a year-over-year growth of approximately 21.4% to 22.0% compared to Q4 2024. When excluding the China region's impact, revenue growth was higher, approximately 23.2% to 23.8%.

Full Year 2025 Financial Overview

For the entire year of 2025, Penumbra's revenue totaled between $1,401.3 million and $1,403.1 million. This reflects an annual growth of approximately 17.3% to 17.5% from 2024. Excluding the China region, the revenue growth for the year was robust at 24.7% to 24.9%.

Gross and Operating Margins

Penumbra reported a gross margin of 67.9% to 68.1% for the fourth quarter and 67.1% for the complete year of 2025. The company achieved an income from operations ranging from $56.9 million to $60.4 million, translating to an operating margin of 14.8% to 15.7% in Q4. For the full year, the income from operations fell between $186.9 million and $190.4 million, resulting in an operating margin of 13.3% to 13.6%.

About Penumbra, Inc.

Penumbra, Inc. focuses on creating innovative technologies to address severe medical conditions including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. The company’s diverse portfolio, including advanced computer-assisted vacuum thrombectomy (CAVT) devices, aims to enhance patient care by efficiently removing blood clots in various settings. With operations in over 100 countries, Penumbra is dedicated to improving patient outcomes and quality of life.

For more information about Penumbra and its initiatives, visit www.penumbrainc.com and follow the company on Instagram, LinkedIn, and X.

Contact Information

For investor relations inquiries, please contact:

Email: investor.relations@penumbrainc.com

Related News